Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but …

  • 0 views
  • 23 Jan, 2021
  • 16 locations
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)

The purpose of this study is to investigate the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) in atrial fibrillation patients with intermediate stroke risk (CHA2DS2

  • 0 views
  • 25 Jan, 2021
Study of Octaplex a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

To demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under Vitamin K Antagonist (VKA) therapy with the need for urgent surgery with significant bleeding risk is

  • 0 views
  • 26 Jan, 2021
  • 77 locations
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in ~5% of patients which prohibits the use of …

  • 11 views
  • 26 Jan, 2021
  • 1 location
Study of Rivaroxaban for CeREbral Venous Thrombosis

SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.

  • 1 views
  • 25 Jan, 2021
  • 13 locations
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study

apixaban
rivaroxaban
edoxaban
anticoagulation therapy
vitamin k antagonist
  • 35 views
  • 22 Jan, 2021
  • 25 locations
The ARIES HeartMate 3 Pump IDE Study

antagonist with aspirin versus vitamin K antagonist with placebo

heart failure
aspirin
  • 5 views
  • 16 May, 2021
  • 31 locations
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown

apixaban
antiplatelet agents
embolism
infarct
stroke
  • 0 views
  • 25 Jan, 2021
  • 1 location
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

European guidelines recommend that the timing of the initiation of non-vitamin K antagonist oral anticoagulants (NOACs) for AF patients with cerebral infarction or TIA is association with stroke severity

deficit
infarct
stroke
diabetes
coagulation factor
  • 13 views
  • 11 Feb, 2021
  • 1 location
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in …

edoxaban
thromboembolism
heparin
probe
anticoagulant therapy
  • 0 views
  • 28 Jan, 2021
  • 170 locations